newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Announces Pipeline Priorities for 2023

gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical